This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. No representation is made as to the safety or effectiveness of 4D-310, 4D-125, or 4D-110 for the therapeutic use for which they are being studied.Ĭautionary Note Regarding Forward-Looking Statements 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.ĤD-310, 4D-125 and 4D-110 are the company’s product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. 4DMT is currently advancing five product candidates in clinical development: 4D-310 for Fabry disease, 4D-125 for XLRP, 4D-150 for wet AMD, 4D-710 for cystic fibrosis and 4D-110 for choroideremia. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
#4d molecular therapeutics phone full#
4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products.
#4d molecular therapeutics phone registration#
6105, or by email at Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at or by accessing the SEC’s website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.ĤDMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. LLC, 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. Copies of the final prospectus relating to the offering may be obtained, when available, from: Goldman Sachs & Co. Copies of the registration statement can be accessed through the SEC's website at This offering is being made only by means of a written prospectus, forming a part of the effective registration statement. LLC, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering.Ī registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on October 28, 2021. The offering is expected to close on November 2, 2021, subject to satisfaction of customary closing conditions. All of the shares in the offering are to be sold by 4D Molecular Therapeutics. In addition, 4D Molecular Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $118.8 million before deducting underwriting discounts and commissions and other offering expenses.
(Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $25.00 per share. 28, 2021 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc.
0 kommentar(er)
